INTRODUCTION
Psoriasis, which affects 1-3% of the world's population, is a multifactorial, dermatological disease. 1 It is associated with genetic and environmental factors. 2, 3 Previous studies reported that psoriasis patients were found to have a two-fold increased risk of cardiovascular disease compared with healthy individuals. 4, 5 Furthermore, some studies reported increased levels of plasma homocysteine and a decreased folic acid concentration in psoriasis patients. 4, 6 Today, hyperhomocysteinemia is a recognised risk factor for cardiovascular diseases and psoriasis. 4, 7 The MTHFR enzyme plays a major role in homocysteine and folic acid metabolism. This enzyme is responsible for the irreversible conversion to 5 methyl tetrahydrofolate, which is a methyl donor of 5,10 methylenetetrahydrofolate. 8 The MTHFR is located on the 1p36.3 locus and many polymorphisms have been identified in the MTHFR. 9 C to T substitution in the MTHFR is located on the 677 th nucleotide, a missense mutation on the 4th exon. MTH-FR C677T polymorphism results in a valine to alanine exchange at the 222 nd codon. This leads to an MTHFR enzyme with decreased enzymatic activity. Mutation is the most common genetic cause of increased homocysteine levels. 10 These frequently seen polymorphisms were found to be associated with cardiovascular diseases, cancer, chronic idiopathic acrocyanosis and homocysteinemia, which is a risk factor for developing psoriasis. 14 The control group was selected randomly and comprised 77 psoriasis-free individuals whose relatives were also psoriasis-free.
Sample preparation
Four ml of venous blood were taken from the subjects and transferred to tubes with EDTA. The DNA isolation of the blood samples collected from both groups was performed by a salting out method and the DNA samples were stored +4C°. 
Statistical Analysis
The (49.4) subjects from the control group (p=0.031) (Table 3) .
Moreover, no relationship was found between the positive family history and early onset of psoriasis or MTHFR C677T polymorphism (p=0.451, p=0.127).
DISCUSSION
In this study, we found that MTHFR C677T polymorphism influences the risk of psoriasis in southern Turkey. We show that there are significant differences between psoriasis and controls for mentioned polymorphism. In addition, our study was the first report on psoriasis patients from southern Turkey, the population of which is ethnically distinct from that of other Turkish regions.
In previous studies, significant links of varying degrees were found between MTHFR C677T polymorphism and psoriasis. 13, 16 The initial study on this relationship was performed in Chinese patients by Baiqui et al. in 2000. They found an increased TT genotype of MTHFR C677T polymorphism in psoriasis patients, compared with the control group. 16 Vasku et al. investigated MTH-FR C677T polymorphisms in patients from the Czech Republic and found an increased frequency of the CC genotype compared with the control group. 13 However, in their study, the TT genotype was more frequent only in psoriasis patients with a positive family history of the disease. Moreover, certain data from studies
show that there is increase of the psoriasis risk for MTHFR C677T polymorphism in northern Turkey and Iran. 17, 18 Our results support the aforementioned studies, as we found that the TT genotype was higher in the psoriasis group than in the control group (p=0.013).
Nevertheless, some studies, including of Malaysian and Caucasian individuals, found no association between psoriasis and controls for MTHFR C677T polymorphism. 19, 20 These contradictory results may be attributable to ethnic differences.
MTHFR C677T polymorphism is important for drug usage. 
